Compare Sirius XM Holdings Inc (SIRI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sirius XM Holdings Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Sirius XM Holdings Inc trades at $28.71 (market cap $9.71B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 13.8× Sirius XM Holdings Inc's market cap, and Sirius XM Holdings Inc pays a 3.75% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| SIRI | VRTX | |
|---|---|---|
Market Cap | $9.71B | $134.06B |
Sector | Media | Health |
52-Week High | $32.59 | $557.96 |
52-Week Low | $19.92 | $376.62 |
Enterprise Value | $18.99B | $128.18B |
Dividend Yield | 3.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sirius XM Holdings Inc. (SIRI) trades at $28.80, down 0.66% today, with a bullish technical signal from moving averages and a consensus analyst price target of $34.86. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026. Financials show a net income margin of 10.23% for 2025, with revenue at $8.56B, while the balance sheet indicates a debt-to-asset ratio improvement to 35.63% in 2025. Recent news highlights a YouTube partnership expected to boost EBITDA by 2029.
The outlook for SIRI is positive, supported by analyst upgrades and institutional buying, but risks include competitive pressures in audio streaming and reliance on advertising growth. The stock's valuation metrics, such as a P/E of 11.57 and P/B of 0.82, suggest potential upside if earnings improve, though volatility from market sentiment remains a concern.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
